HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease.
Chronic carriers of hepatitis B virus (HBV) who have to be immunosuppressed are at risk for HBV reactivation and hepatitis. Continuing immunosuppression in such patients and in immunosuppressed patients with active hepatitis B is strongly discouraged yet frequently inevitable. We here report on both the successful control of hepatitis and seroconversion after HBV reactivation following allogeneic hematopoietic stem cell transplantation (HSCT) with entecavir despite systemic immunosuppression.
Christopeit
Maximilian
M
Department of Internal Medicine, Internal Medicine IV, Oncology and Hematology, University Hospital Halle, Saale, and Institute for Medical Microbiology, University Halle, Salle, Ernst-Grube-Strasse 40, 06097 Halle, Saale, Germany.
Weber
Thomas
T
Abendroth
Jens
J
Dollinger
Matthias
M
Lübbert
Christoph
C
Oehme
Albrecht
A
Kekulé
Alexander S
AS
Behre
Gerhard
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications* / Q000188:drug therapy; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000175:diagnosis*; D006510:Hepatitis B Antibodies / Q000097:blood; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008875:Middle Aged; D016896:Treatment Outcome
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D007166:Immunosuppressive Agents; C413685:entecavir; D006147:Guanine